KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Non-Current Liabilities (2016 - 2025)

Biomarin Pharmaceutical's Total Non-Current Liabilities history spans 17 years, with the latest figure at $1.4 billion for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 12.82% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Dec 2025, up 12.82%, and an annual FY2025 reading of $1.4 billion, up 12.82% over the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $1.4 billion at Biomarin Pharmaceutical, down from $1.4 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $1.8 billion in Q4 2023, with the low at $1.2 billion in Q4 2024.
  • Average Total Non-Current Liabilities over 5 years is $1.6 billion, with a median of $1.6 billion recorded in 2022.
  • Year-over-year, Total Non-Current Liabilities rose 16.6% in 2021 and then plummeted 32.09% in 2024.
  • Tracing BMRN's Total Non-Current Liabilities over 5 years: stood at $1.7 billion in 2021, then decreased by 3.02% to $1.7 billion in 2022, then grew by 5.87% to $1.8 billion in 2023, then plummeted by 32.09% to $1.2 billion in 2024, then rose by 12.82% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Total Non-Current Liabilities are $1.4 billion (Q4 2025), $1.4 billion (Q3 2025), and $1.3 billion (Q2 2025).